Allergan plc (AGN)

140.31
NYSE
Prev Close 140.31
Day Low/High 0.00 / 0.00
52 Wk Low/High 125.84 / 197.00
Exchange NYSE
Shares Outstanding 330.22B
Market Cap 46.33B
Div & Yield N.A. (N.A)

Latest News

Allergan Earns 2019 ENERGY STAR® Partner Of The Year - Sustained Excellence Award For The Sixth Consecutive Year

Allergan Earns 2019 ENERGY STAR® Partner Of The Year - Sustained Excellence Award For The Sixth Consecutive Year

- Company Recognized for Continued Superior Energy Achievements -

Allergan To Report First Quarter 2019 Financial Results And Host Conference Call And Webcast

Allergan To Report First Quarter 2019 Financial Results And Host Conference Call And Webcast

DUBLIN, April 9, 2019 /PRNewswire/ -- Allergan plc (NYSE: AGN) today announced it will release first quarter 2019 financial results on Tuesday, May 7, 2019, prior to the open of U.

Allergan 360° Aesthetics Report™ Reveals Evolving Beauty Perceptions And Diverse Priorities Around The World

Allergan 360° Aesthetics Report™ Reveals Evolving Beauty Perceptions And Diverse Priorities Around The World

Digital Boom and Millennials are Growing the Category, Wellness and Self-Care are New Key Drivers, Interest is in Eyes and Body Contouring

Allergan 360° Aesthetics Report™ Reveals Evolving Beauty Perceptions And Diverse Priorities Around The World

Allergan 360° Aesthetics Report™ Reveals Evolving Beauty Perceptions And Diverse Priorities Around The World

Digital Boom and Millennials are Growing the Category, Wellness and Self-Care are New Key Drivers, Interest is in Eyes and Body Contouring

Aegon Publishes Agenda For 2019 Annual General Meeting

Aegon Publishes Agenda For 2019 Annual General Meeting

Today, Aegon N.V.

Allergan And Molecular Partners Announce Topline Safety Results From MAPLE Study Of Abicipar Pegol

Allergan And Molecular Partners Announce Topline Safety Results From MAPLE Study Of Abicipar Pegol

The MAPLE study used a modified manufacturing process and demonstrated decreased intraocular inflammation

Aegon Prices EUR 500 Million Restricted Tier 1 Securities

Aegon Prices EUR 500 Million Restricted Tier 1 Securities

Today, Aegon successfully priced its inaugural EUR 500 million Restricted Tier 1 perpetual contingent convertible securities, with a fixed coupon of 5.

More Mud on Johnson & Johnson?

More Mud on Johnson & Johnson?

There's been enough news with the lawsuits around this name to get the emotion back into the stock. Emotion often leads to volatility.

Allergan Acquires Envy Medical, Inc., Adding Skin Resurfacing Dermalinfusion System To Best-in-Class Medical Aesthetics Portfolio

Allergan Acquires Envy Medical, Inc., Adding Skin Resurfacing Dermalinfusion System To Best-in-Class Medical Aesthetics Portfolio

- Proprietary Skin Resurfacing Treatment for the Face and Body Reinforces Allergan's Commitment to Skin Quality -

Aegon Publishes 2018 Integrated Annual Report

Aegon Publishes 2018 Integrated Annual Report

Today, Aegon N.V.

CoolSculpting® And Sonja Morgan Partner To Talk Bikini Denial

CoolSculpting® And Sonja Morgan Partner To Talk Bikini Denial

-- Television Personality is Spokesperson for the World's #1 Nonsurgical Fat Reduction Treatment* --

Allergan Announces FDA Approval Of AVYCAZ® (ceftazidime And Avibactam) For Pediatric Patients

Allergan Announces FDA Approval Of AVYCAZ® (ceftazidime And Avibactam) For Pediatric Patients

- Label Now Includes New Data on Use of AVYCAZ for Treatment of cUTI and cIAI in Pediatric Patients 3 Months of Age and Older -

Jim Cramer: AAPL Should Get Into Diabetes Treatment and KHC Should Invest in Pot

Jim Cramer: AAPL Should Get Into Diabetes Treatment and KHC Should Invest in Pot

In this day and age, companies must be 'disruptors' or get left in the dust.

Allergan Announces FDA Acceptance Of New Drug Application For Ubrogepant For The Acute Treatment Of Migraine

Allergan Announces FDA Acceptance Of New Drug Application For Ubrogepant For The Acute Treatment Of Migraine

- Ubrogepant Seeks to be the First Oral Calcitonin Gene-Related Peptide (CGRP) Receptor Antagonist for the Acute Treatment of Migraine -

Watching Shares of Och-Ziff Capital Management

Watching Shares of Och-Ziff Capital Management

With shares breaking above the recent, albeit small, pennant, there might be reason for optimism.

The 6 Stocks To Watch: Cramer's 'Mad Money' Recap (Thursday 3/7/19)

The 6 Stocks To Watch: Cramer's 'Mad Money' Recap (Thursday 3/7/19)

Jim Cramer's watching six stocks to determine when the selling will end.

Could Kroger Lose the Grocery Wars Over This Challenge?

Could Kroger Lose the Grocery Wars Over This Challenge?

Allergan is another stock that could stay stuck in its Doldrums. See which of its peers Jim Cramer likes better and why.

Activists Aim to Eliminate Dual Role for Allergan CEO Saunders

Activists Aim to Eliminate Dual Role for Allergan CEO Saunders

David Tepper's Appaloosa LP renews calls for changes at the top.

Allergan Rises After FDA Accepts License Applications for Botox Supplements

Allergan Rises After FDA Accepts License Applications for Botox Supplements

Allergan wants Botox licenses for pediatric patients.

Jim Cramer: No Room for Cynicism, JNJ's New Depression Drug Is Lifesaving

Jim Cramer: No Room for Cynicism, JNJ's New Depression Drug Is Lifesaving

The approval of esketamine, known as Spravato, for use against severe depression is special -- it is saving lives.

Allergan Announces Phase 3 Results For Rapastinel As An Adjunctive Treatment Of Major Depressive Disorder (MDD)

Allergan Announces Phase 3 Results For Rapastinel As An Adjunctive Treatment Of Major Depressive Disorder (MDD)

-- Three acute pivotal studies did not meet their primary endpoint --

Allergan To Present At The Cowen And Company 39th Annual Health Care Conference

Allergan To Present At The Cowen And Company 39th Annual Health Care Conference

DUBLIN, March 4, 2019 /PRNewswire/ -- Allergan plc (NYSE: AGN), a leading global biopharmaceutical company, today announced that Chief Financial Officer Matthew Walsh will participate in a fireside chat at the Cowen and Company 39 th Annual Health Care...

Allergan Presents Data From Seven Abstracts At The 2019 American Academy Of Dermatology (AAD) In Washington D.C.

Allergan Presents Data From Seven Abstracts At The 2019 American Academy Of Dermatology (AAD) In Washington D.C.

DUBLIN, March 1, 2019 /PRNewswire/ -- Allergan plc (NYSE: AGN) today announced that its data will be featured during the 2019 American Academy of Dermatology (AAD) Annual Meeting in Washington D.

Allergan Responds To Public Shareholder Letter

Allergan Responds To Public Shareholder Letter

DUBLIN, Feb. 19, 2019 /PRNewswire/ -- Allergan plc (NYSE: AGN) today issued the following statement from its Board of Directors in response to a public shareholder letter: "While we appreciate the input of Appaloosa as we do all of our shareholders, we...

Robert J. Hugin Appointed To Allergan Board Of Directors

Robert J. Hugin Appointed To Allergan Board Of Directors

- Sixth New Director Since 2017 as Part of Allergan's Transformation from a Generic to a Branded Biopharmaceutical Company -

ALLERGAN 24 HOUR DEADLINE ALERT: Approximately 24 Hours Remain; ClaimsFiler Reminds Investors With Losses In Excess Of $100,000 Of Deadline In Class Action Lawsuit Against Allergan Plc. - AGN

ALLERGAN 24 HOUR DEADLINE ALERT: Approximately 24 Hours Remain; ClaimsFiler Reminds Investors With Losses In Excess Of $100,000 Of Deadline In Class Action Lawsuit Against Allergan Plc. - AGN

ClaimsFiler, a FREE shareholder information service, reminds investors that they have only until February 19, 2019 to file lead plaintiff applications in a securities class action lawsuit against Allergan plc.

TheStreet Quant Rating: D+ (Sell)